今日盘中，新上市的制药公司海西新药（02637）股价大涨21.53%，引起市场广泛关注。这家备受期待的新股今天正式在港交所挂牌交易，其强劲表现与其火爆的IPO认购情况密切相关。
据悉，海西新药此前公布的招股结果显示，公司以每股86.40港元的上限价格定价，募集资金净额约9.4亿港元。值得注意的是，其香港公开发售部分获得了惊人的3165.1倍超额认购，反映了投资者对该股的巨大兴趣。今日开盘价为102港元，较发行价上涨18.06%，随后在交易过程中继续走高。
分析人士指出，海西新药的强劲表现可能源于其在仿制药市场的领先地位和良好的财务表现。公司的核心产品在多个治疗领域占据重要市场份额，包括心血管、消化系统等。此外，公司近年来业绩增长迅速，从2022年到2024年，营收从2.12亿元增长至4.67亿元，净利润也从6898万元增至1.36亿元。这些因素共同推动了投资者的热情，促使股价在上市首日出现大幅上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.